Immunitasbio Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 09-11-2024
- Paid Up Capital ₹ 0.10 M
as on 09-11-2024
- Company Age 3 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 79.74%
(FY 2023)
- Profit 133.99%
(FY 2023)
- Ebitda 76.06%
(FY 2023)
- Net Worth 222.75%
(FY 2023)
- Total Assets 203.86%
(FY 2023)
About Immunitasbio
The Corporate was formerly known as Immunitas Biosciences Private Limited. The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Sivasankar Baalasubramanian, James Hindley, Maheshvarane Vishwanath, and One other member serve as directors at the Company.
- CIN/LLPIN
U85110KA2021PTC144382
- Company No.
144382
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Feb 2021
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Immunitasbio?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sivasankar Baalasubramanian  | Director | 01-Dec-2022 | Current |
James Hindley  | Director | 25-Mar-2024 | Current |
| Maheshvarane Vishwanath | Director | 19-Feb-2021 | Current |
| Vasuky | Director | 19-Feb-2021 | Current |
Financial Performance of Immunitasbio.
Immunitasbio Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 79.74% increase. The company also saw a substantial improvement in profitability, with a 133.99% increase in profit. The company's net worth Soared by an impressive increase of 222.75%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Immunitasbio?
Unlock access to Immunitasbio's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Immunitasbio?
Immunitasbio has a workforce of 0 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Immunitasbio, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Immunitasbio's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
